Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
1. Enveric received a patent for novel aminated tryptamine derivatives. 2. These compounds aim to provide non-hallucinogenic mental health treatments. 3. Potential applications include depression and anxiety therapies. 4. Innovations align with trends in outpatient treatment models. 5. Strengthened IP portfolio enhances future growth opportunities.